Canlyniadau Chwilio - Matthew D. Hellmann

Mireinio'r Canlyniadau
  1. 1
    PD-1/PD-L1 Axis in Lung Cancer

    PD-1/PD-L1 Axis in Lung Cancer gan Fernando C. Santini, Matthew D. Hellmann

    Cyhoeddwyd 2018
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Acquired Resistance to Immune Checkpoint Inhibitors

    Acquired Resistance to Immune Checkpoint Inhibitors gan Adam J. Schoenfeld, Matthew D. Hellmann

    Cyhoeddwyd 2020
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Chemotherapy remains an essential element of personalized care for persons with lung cancers

    Chemotherapy remains an essential element of personalized care for persons with lung cancers gan Matthew D. Hellmann, Bingyu Li, Jamie E. Chaft, Mark G. Kris

    Cyhoeddwyd 2016
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer

    How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer gan Solange Peters, M. Reck, Egbert F. Smit, Tony Mok, Matthew D. Hellmann

    Cyhoeddwyd 2019
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    Opportunistic infections in patients treated with immunotherapy for cancer

    Opportunistic infections in patients treated with immunotherapy for cancer gan Chrisann Kyi, Matthew D. Hellmann, Jedd D. Wolchok, Paul B. Chapman, Michael A. Postow

    Cyhoeddwyd 2014
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors

    Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors gan Jamie E. Chaft, Matthew D. Hellmann, Moises J. Velez, William D. Travis, Valerie W. Rusch

    Cyhoeddwyd 2017
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers

    Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers gan Jia Luo, Hira Rizvi, Jacklynn V. Egger, Isabel R. Preeshagul, Jedd D. Wolchok, Matthew D. Hellmann

    Cyhoeddwyd 2020
    Cael y testun llawn
    Carta
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing

    Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing gan Helena A. Yu, Maria E. Arcila, Matthew D. Hellmann, Mark G. Kris, Marc Ladanyi, Gregory J. Riely

    Cyhoeddwyd 2014
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Clinical Characterization of Immunotherapy-Related Pruritus Among Patients Seen in 2 Oncodermatology Clinics

    Clinical Characterization of Immunotherapy-Related Pruritus Among Patients Seen in 2 Oncodermatology Clinics gan Gregory S. Phillips, Azael Freites‐Martínez, Jennifer Wu, Donald Chan, Gabriella Fabbrocini, Matthew D. Hellmann, Mario E. Lacouture

    Cyhoeddwyd 2018
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphoma

    Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphoma gan Jeremy S. Abramson, Matthew D. Hellmann, Jeffrey A. Barnes, Peter S. Hammerman, Christiana E. Toomey, Tak Takvorian, Alona Muzikansky, Ephraim P. Hochberg

    Cyhoeddwyd 2010
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    Multiple Resolution Residually Connected Feature Streams for Automatic Lung Tumor Segmentation From CT Images

    Multiple Resolution Residually Connected Feature Streams for Automatic Lung Tumor Segmentation From CT Images gan Jue Jiang, Yu‐Chi Hu, Chia‐Ju Liu, Darragh Halpenny, Matthew D. Hellmann, Joseph O. Deasy, G Mageras, Harini Veeraraghavan

    Cyhoeddwyd 2018
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  12. 12
    Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas

    Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas gan Juliana Schilsky, Ai Ni, Linda S. Ahn, Sutirtha Datta, William D. Travis, Mark G. Kris, Jamie E. Chaft, Natasha Rekhtman, Matthew D. Hellmann

    Cyhoeddwyd 2017
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  13. 13
    Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types

    Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types gan Aparna Chhibber, Lingkang Huang, Hong Zhang, Jialin Xu, Rǎzvan Cristescu, Xiao Liu, Devan V. Mehrotra, Judong Shen, Peter Shaw, Matthew D. Hellmann, Alexandra Snyder

    Cyhoeddwyd 2022
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  14. 14
    Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas

    Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas gan Juliana Eng, Kaitlin M. Woo, Camelia S. Sima, Andrew J. Plodkowski, Matthew D. Hellmann, Jamie E. Chaft, Mark G. Kris, Maria E. Arcila, Marc Ladanyi, Alexander Drilon

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  15. 15
    PS2 CheckMate 227: Nivolumab + Ipilimumab vs Chemotherapy as 1L Treatment for Advanced NSCLC With High Tumor Mutational Burden

    PS2 CheckMate 227: Nivolumab + Ipilimumab vs Chemotherapy as 1L Treatment for Advanced NSCLC With High Tumor Mutational Burden gan Clarissa Mathias, Martin Reck, Matthew D. Hellmann, Suresh S. Ramalingam, Julie R. Brahmer, Kenneth J. O’Byrne, Prabhu Bhagavatheeswaran, Faith E. Nathan, Hossein Borghaei, Luis Paz‐Ares

    Cyhoeddwyd 2018
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  16. 16
    Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

    Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib gan Adam J. Schoenfeld, Kathryn C. Arbour, Hira Rizvi, Afsheen Iqbal, Shirish M. Gadgeel, Jeffrey Girshman, Mark G. Kris, Gregory J. Riely, Helena A. Yu, Matthew D. Hellmann

    Cyhoeddwyd 2019
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  17. 17
    Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade

    Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade gan Tavi Nathanson, Arun Ahuja, Alex Rubinsteyn, Bülent Arman Aksoy, Matthew D. Hellmann, Diana Miao, Eliezer M. Van Allen, Taha Merghoub, Jedd D. Wolchok, Alexandra Snyder, Jeff Hammerbacher

    Cyhoeddwyd 2016
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  18. 18
    Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC

    Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC gan Laurent Dercle, Matthew Fronheiser, Naiyer A. Rizvi, Matthew D. Hellmann, Sabine Maier, Wendy Hayes, Hao Yang, Pingzhen Guo, Tito Fojo, Lawrence H. Schwartz, Binsheng Zhao, David Leung

    Cyhoeddwyd 2023
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  19. 19
    Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers

    Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers gan Anya M. Litvak, Paul K. Paik, Kaitlin M. Woo, Camelia S. Sima, Matthew D. Hellmann, Maria E. Arcila, Marc Ladanyi, Charles M. Rudin, Mark G. Kris, Gregory J. Riely

    Cyhoeddwyd 2014
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  20. 20
    Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders

    Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders gan Giulia C. Leonardi, Justin F. Gainor, Mehmet Altan, Sasha Kravets, Suzanne E. Dahlberg, Lydia Gedmintas, Roxana Azimi, Hira Rizvi, Jonathan W. Riess, Matthew D. Hellmann, Mark M. Awad

    Cyhoeddwyd 2018
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: